Blockchain Registration Transaction Record

IceCure's ProSense® Cryoablation Therapy Shows Promising Results for Early-Stage Breast Cancer

IceCure Medical Ltd. reports promising results for ProSense® cryoablation therapy, bringing a potential new standard of care treatment for early-stage breast cancer. With a 96.3% recurrence-free rate, the therapy offers a minimally invasive and cost-efficient alternative to traditional surgery.

IceCure's ProSense® cryoablation therapy offers a minimally invasive, effective, and potentially more cost-efficient alternative to traditional lumpectomy surgery for early-stage breast cancer patients. The therapy's high patient and physician satisfaction, along with its 96.3% recurrence-free rate, could significantly improve the treatment options and outcomes for women diagnosed with invasive breast cancer.